OncoSil Medical (ASX:OSL) Net Income (Continuing Operations): A$-12.92 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:OSL OncoSil Medical Ltd ASX:OSL
40 GF Score
Price A$1.17
GF Value A$2.91
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is OncoSil Medical Net Income (Continuing Operations)?

OncoSil Medical ASX:OSL -2.90% 40 Net Income (Continuing Operations) is A$-12.92 Mil as of Dec. 2025. GuruFocus rates ASX:OSL with a GF Score™ of 40/100 and a GF Value™ of A$2.91 (Possible Value Trap). The stock has 4 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. OncoSil Medical's Net Income (Continuing Operations) for the six months ended in Dec. 2025 was A$-4.53 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-12.92 Mil.

OncoSil Medical  (ASX:OSL) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

OncoSil Medical Net Income (Continuing Operations) Related Terms

OncoSil Medical Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for OncoSil Medical's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSil Medical Net Income (Continuing Operations) Chart

OncoSil Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.43 -10.73 -11.34 -12.38 -15.10

OncoSil Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.02 -6.36 -6.71 -8.39 -4.53
ASX:OSL
40GF Score
OncoSil Medical Ltd ASX:OSL
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoSil Medical Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-12.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of A$-12.92 Mil mean?
OncoSil Medical (ASX:OSL) has a Net Income (Continuing Operations) of A$-12.92 Mil as of Dec. 2025. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on OncoSil Medical and its competitors.
Is OncoSil Medical's Net Income (Continuing Operations) too high?
OncoSil Medical's current Net Income (Continuing Operations) is A$-12.92 Mil. Overall, OncoSil Medical has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's Net Income (Continuing Operations) compare to ABT and SYK?
OncoSil Medical's Net Income (Continuing Operations) of A$-12.92 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Medical Devices & Instruments company?
A good Net Income (Continuing Operations) depends on the Medical Devices & Instruments industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on OncoSil Medical and its competitors. OncoSil Medical's current Net Income (Continuing Operations) is A$-12.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.91, compared to a current price of A$1.17 — trading 59.8% below its estimated fair value. The current Net Income (Continuing Operations) is A$-12.92 Mil. OncoSil Medical's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current Net Income (Continuing Operations) is A$-12.92 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoSil Medical (ASX:OSL) Overvalued in 2026?

Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued. The current stock price of A$1.17 is trading 59.8% below its estimated GF Value™ of A$2.91. GuruFocus considers OncoSil Medical to be Possible Value Trap.

Key valuation signals for ASX:OSL:

  • Net Income (Continuing Operations): A$-12.92 Mil
  • GF Value™: A$2.91 vs. price of A$1.17 (59.8% below fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OncoSil Medical Business Description

Address 7 Eden Park Drive, Level 5, Macquarie Park, Sydney, NSW, AUS, 2113
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
40GF Score

Get the complete analysis for ASX:OSL

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.17
Price
A$2.91
GF Value